COMMENTARY
Therapeutic potential of fractalkine
Therapeutic potential of fractalkine: a novel approach to metastatic colon cancer
The First Department of Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Mannheim, Germany
Correspondence to:
Correspondence to:
Dr M Brueckmann
First Department of Medicine, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany; martina.brueckmann@med.ma.uni-heidelberg.de
Fractalkine is involved in the pathogenesis of different types of cancer and in various clinical disease states
| The first 150 words of the full text of this article appear below. |
Several experimental approaches have shown that a variety of chemokines have anti-tumour activity either by chemoattracting natural killer cells, monocytes and macrophages, or by accumulating dendritic cells.1 Accumulating evidence has shown that fractalkine (CX3CL1), the unique member of the CX3C chemokine subfamily, is involved in the pathogenesis of different types of cancer2,3 and in various clinical disease states beyond cancer, such as atherosclerosis, glomerulonephritis, rheumatoid arthritis, HIV disease and sepsis.4–6 In contrast with other chemokines, fractalkine exists in two forms, each mediating distinct biological actions.7 The membrane-anchored protein, which is expressed primarily on the endothelium, serves as an adhesion protein promoting the retention of monocytes and T cells.8 The soluble form originates from extracellular proteolysis by proteases, such as tumour necrosis factor-
converting enzyme (also known as ADAM17) and ADAM10.9 The secreted form resembles more a conventional chemokine and strongly induces chemotaxis and causes migration of
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Relevant Article
- Tissue-specific differential antitumour effect of molecular forms of fractalkine in a mouse model of metastatic colon cancer
- S Vitale, B Cambien, B F Karimdjee, R Barthel, P Staccini, C Luci, V Breittmayer, F Anjuère, A Schmid-Alliana, and H Schmid-Antomarchi
Gut 2007 56: 365-372.[Abstract] [Full Text] [PDF]
- Full Text
- Full Text (PDF)
- Alert me when this article is cited
- Alert me if a correction is posted
- Citation Map
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
